BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241022T080000
DTEND;TZID=Europe/Brussels:20241025T170000
DTSTAMP:20260729T061344
CREATED:20240611T071159Z
LAST-MODIFIED:20240611T071200Z
UID:7930-1729584000-1729875600@www.europabio.org
SUMMARY:World Orphan Drug Congress Europe 2024
DESCRIPTION:The World Orphan Drug Congress Europe is the largest and most established orphan drug & rare disease event worldwide. Meet over 2000 attendees\, hear from 250 leading speakers\, and connect with 130 exhibitors as we bring together experts from the start-to-finish of orphan drugs. From regulation and policy to global pricing and gene therapy\, the Congress has it covered. \n\n\n\nOur attendees include the most senior individuals across the industry\, including; R&D\, Gene Therapy and Rare diseases\, Precision/Personalised Medicine\, Genetic Disorders\, Patient Advocacy and Engagement\, Associations in ATMPs\, Investors\, Regulatory Affairs Professionals\, Governmental Bodies and many more … \n\n\n\nUse code “EUBIO20” to save an additional 20% off the Pharma/Biotech and Standard packages.
URL:https://www.europabio.org/event/world-orphan-drug-congress-europe-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/06/Event-Website-Banner-EBIO-WODC-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241008T100000
DTEND;TZID=Europe/Brussels:20241010T180000
DTSTAMP:20260729T061344
CREATED:20240828T135105Z
LAST-MODIFIED:20240828T135930Z
UID:8158-1728381600-1728583200@www.europabio.org
SUMMARY:CPHI Milan
DESCRIPTION:EuropaBio is pleased to partner with CPHI Milan 2024\, the biggest international pharmaceutical industry event for the thirty fifth anniversary edition. This year’s edition held from the 8th to the 10th of October in Fiera Milano\, Italy promises to a packed agenda with over 150 expert international speakers with over 100 content sessions. \n\n\n\nJoin our Director General Dr Claire Skentelbery this year where she will be speaking on the 9th of October to discuss how cultivated meat has the potential to revolutionise biologic manufacturing. Join her in Hall 3 – 3F97 at 16:15 on 09/10/2024 to find out more. \n\n\n\n \n\n\n\n\nFind Out More & Register Here
URL:https://www.europabio.org/event/cphi-milan/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/08/CPHI-x-EuropaBio-2024-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241002T170000
DTEND;TZID=Europe/Brussels:20241002T193000
DTSTAMP:20260729T061344
CREATED:20240827T080153Z
LAST-MODIFIED:20240827T080535Z
UID:8151-1727888400-1727897400@www.europabio.org
SUMMARY:Enhancing Europe's Pharma and Biotech Competitiveness and Open Strategic Autonomy
DESCRIPTION:Join our Director General Dr Claire Skentelbery on 2 October 2024 where she will be speaking at the Novartis & BritCham event “Enhancing Europe’s Pharma and Biotech Competitiveness and Open Strategic Autonomy”. \n\n\n\n\nFind Out More & Register Here
URL:https://www.europabio.org/event/enhancing-europes-pharma-and-biotech-competitiveness-and-open-strategic-autonomy/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/08/BritCham-Novartis-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240710T080000
DTEND;TZID=Europe/Brussels:20240711T170000
DTSTAMP:20260729T061344
CREATED:20240531T135225Z
LAST-MODIFIED:20240531T135227Z
UID:7893-1720598400-1720717200@www.europabio.org
SUMMARY:CURIOUS­ FUTURE INSIGHT™ CONFERENCE
DESCRIPTION:Over the millennia science & technology have steadily advanced\, but key unsolved challenges remain\, and much more is possible. The Curious – Future Insight™ Conference brings together some of the world’s brightest scientists and most accomplished innovators to present their work and explore the future of science and technology\, solving the challenges of today and enabling the dreams of a better tomorrow. \n\n\n\nThe Curious – Future Insight™ conference featurestop speakers and Nobel laureates from all over theworld\, among them: \n\n\n\n\nEmmanuelle Charpentier\, MPI (2018)\n\n\n\nSteven Chu\, Stanford University (2024)\n\n\n\nRobert Langer\, MIT (2024)\n\n\n\nSatya Nadella\, CEO Microsoft (2018)\n\n\n\nUğur Şahin\, CEO BioNTech (2024)\n\n\n\nRandy Schekman\, Berkeley (2024)\n\n\n\nThomas C. Südhof\, Stanford University (2024\, 2022)\n\n\n\nCraig Venter\, Craig Venter Institute (2018)
URL:https://www.europabio.org/event/curious-future-insight-conference/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Curious-Insights-Banner-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240416T083000
DTEND;TZID=Europe/Brussels:20240416T120000
DTSTAMP:20260729T061344
CREATED:20240326T082922Z
LAST-MODIFIED:20240326T083218Z
UID:7614-1713256200-1713268800@www.europabio.org
SUMMARY:RARE DISEASES FORUM 2024
DESCRIPTION:Against the backdrop of the Belgian EU Council Presidency\, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations\, industry and policy to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda. \n\n\n\n \n\n\n\nAbout ‘The Rare Diseases Forum 2024: Securing Europe’s Competitiveness in R&D for people living with rare diseases’ features keynotes and panel discussions with a focus on the EU’s role in enhancing competitiveness in life sciences\, fostering investment in the rare diseases sector\, and examining the benefits of a competitive agenda for those with rare diseases.  \n\n\n\nThe event is convened by Global Counsel on behalf of the forum partners\, EURORDIS\, RaDiOrg\, EFPIA\, Eucope\, EuropaBio\, Pharma.be\, UCB\, Novo Nordisk\, Sanofi & Takeda.
URL:https://www.europabio.org/event/rare-diseases-forum-2024/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/03/Event-Banner-Website-updated.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240307T130000
DTEND;TZID=Europe/Brussels:20240307T143000
DTSTAMP:20260729T061344
CREATED:20240209T095401Z
LAST-MODIFIED:20240306T151454Z
UID:7385-1709816400-1709821800@www.europabio.org
SUMMARY:EuropaBio Webinar – How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies?
DESCRIPTION:Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies. \n\n\n\nFollowing the publication on 24 January 2024 of a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem\, EuropaBio is delighted to invite you to attend its exclusive webinar to discuss the consequences of this landmark legislation for the future of innovation in healthcare in Europe\, EU patients and economies within a global race towards health security and competitiveness. \n\n\n\nThe event will start with a presentation of the study by Charles Rivers Associates and will be followed by a panel discussion featuring leading voices of the European biotechnology ecosystem to discuss the impact of the proposed legislation and its consequences on the development of breakthrough medicines for EU patients. \n\n\n\nThe webinar will take place on Thursday 7 March at 13.00 CET. If you wish to attend\, please register below. \n\n\n\nAgenda: \n\n\n\n\nWelcome & Introduction: 13:00 – 13:05\, Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n\nReport Presentation and Q&A: 13:05 – 13:30\, Antun Sablek & Tim Wilsdon\, Charles River Associates\n\n\n\nPanel Discussion and Q&A: 13:30 – 14:25\, Panelists: John James Ricketts\, Noel Minnis\, Thomas Bols\, Tineke Van hooland\, Wojciech Nowak and Yordan Aleksandrov. Moderated by Dr Claire Skentelbery.\n\n\n\nConcluding Remarks: 14:25 – 14:30 Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n \n\n\n\nSpeakers: Moderated by Dr Claire Skentelbery\, EuropaBio \n\n\n\n\nAntun Sablek\, Charles River Associates\n\n\n\nJohn James Ricketts\, Eli Lilly\n\n\n\nNoel Minnis\, Takeda\n\n\n\nThomas Bols\, PTC Therapeutics\n\n\n\nTim Wilsdon\, Charles River Associates\n\n\n\nTineke Van hooland\, Bio.be\n\n\n\nWojciech Nowak\, Novartis\n\n\n\nYordan Aleksandrov\, Pfizer\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/europabio-webinar-how-will-the-revision-eu-general-pharmaceutical-legislation-impact-europes-innovation-ecosystem-and-biotechnology-companies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/CRA-Webinar-Banner-Event-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240229T090000
DTEND;TZID=Europe/Brussels:20240301T170000
DTSTAMP:20260729T061344
CREATED:20240214T085311Z
LAST-MODIFIED:20240214T100345Z
UID:7415-1709197200-1709312400@www.europabio.org
SUMMARY:International Congress on Rare Diseases and Orphan Drugs 2024
DESCRIPTION:Navigating the Uncharted: Advancements\, Collaborations\, and Hope in Rare Diseases \n\n\n\nSupported by EuropaBio \n\n\n\n \n\n\n\nAbout the event: \n\n\n\nEmbrace the extraordinary journey into the world of rare diseases at our groundbreaking International Congress\, where innovation\, collaboration\, and hope converge! \n\n\n\nThe International Congress on Rare Diseases and Orphan Drugs is organized by Rare Diseases Greece (RDG)\, member of EURORDIS-Rare Diseases Europe and Boussias Events. \n\n\n\nFollowing the success of the previous years and having advanced the policy agenda on both a national and international level\, the Organizing Committee – consisting of Rare Diseases Greece (RDG)\, the 30-member umbrella organization that represents the country’s rare disease community\, brings together all the key initiatives and stakeholders currently shaping the rare disease landscape with the aim to set a course for the future of rare diseases. \n\n\n\nAttendance details: \n\n\n\nThursday\, 29.02.2024 (Hybrid | Technopolis City of Athens Gasholder 1 – Auditorium “Miltiadis Evert”) & Friday\, 01.03.2024 (Digital) \n\n\n\n \n\n\n\n\nRegister here\n\n\n\n\n \n\n\n\n\nFind out more here
URL:https://www.europabio.org/event/international-congress-on-rare-diseases-and-orphan-drugs-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/Event-Banner-International-Congress-on-Rare-Diseases-Orphan-Drugs-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240214T080000
DTEND;TZID=Europe/Brussels:20240214T170000
DTSTAMP:20260729T061344
CREATED:20240130T125205Z
LAST-MODIFIED:20240130T125207Z
UID:7333-1707897600-1707930000@www.europabio.org
SUMMARY:Europe Rare Disease Summit 2024
DESCRIPTION:How to improve and learn about Government Plans\, Access & Financing\, Clinical Research and Innovation\, Artificial Intelligence and Data\, and Social & Patient. \n\n\n\nJoin our very own Healthcare Policy Senior Manager\, Adrien Samson in Madrid where he will be speaking in the panel “Innovation\, Funding and Access to Orphan Drugs: Challenges and Opportunities” between 12:15 and 13:00. \n\n\n\n \n\n\n\nWe are thrilled to announce the eagerly awaited second edition of the Europe Rare Disease Summit\, set to take place in February. Joining forces from all corners of Europe\, this prestigious event brings together leading researchers\, healthcare professionals\, patient advocates\, policymakers\, industry experts\, and rare disease patients and families. \n\n\n\nThe summit emphasizes the power of collaboration and solidarity in facing rare diseases. Together\, we can accelerate research\, enhance patient care\, and improve outcomes\, offering a brighter future for those affected by rare diseases. \n\n\n\nKey Objectives: \n\n\n\nEmpowering Patients: Putting patients at the heart of our efforts\, we strive to enhance their access to quality care and support\, while advocating for their rights and unique challenges. \n\n\n\nAdvancing Research: Renowned scientists will present groundbreaking discoveries\, fostering cross-disciplinary collaboration to propel rare disease research forward. \n\n\n\nBuilding Collaborative Networks: A platform for stakeholders to connect\, exchange ideas\, and form strategic partnerships\, bridging gaps in research\, treatment\, and support. \n\n\n\nInfluencing Policy: By engaging policymakers\, we seek to drive positive changes and better support the rare disease community. \n\n\n\nEngaging Program Highlights: Expect a dynamic lineup of keynote speeches\, interactive workshops\, panel discussions and networking opportunities. Share experiences\, learn from experts\, and inspire change. \n\n\n\nLocation and Dates: Prepare to be inspired in the vibrant setting of Madrid on February 14th. \n\n\n\nWho will Attend: \n\n\n\nRare Disease AdvocatesResearchers and ScientistsHealthcare ProfessionalsIndustry LeadersPolicymakers and Government RepresentativesPharmaceutical and Biotech CompaniesInvestors and Venture CapitalistsAcademics and Students
URL:https://www.europabio.org/event/europe-rare-disease-summit-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/Event-Banner-ERDS-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240124T120000
DTEND;TZID=Europe/Brussels:20240124T150000
DTSTAMP:20260729T061344
CREATED:20240109T104014Z
LAST-MODIFIED:20240116T095205Z
UID:7234-1706097600-1706108400@www.europabio.org
SUMMARY:EU pharmaceutical legislation - Europe’s biotech innovation in the balance?
DESCRIPTION:Event agenda \n\n\n\n12:00: Registration opens \n\n\n\n12:30: Panel starts \n\n\n\n13:45: Panel close and networking lunch \n\n\n\n15:00: Close \n\n\n\nConfirmed Speakers \n\n\n\nTomislav Sokol MEPMember SANT Committee\, European Parliament \n\n\n\nHilde StevensCo-director\, Institute for Interdisciplinary Innovation in Healthcare (I3H)\, ULB \n\n\n\nKristin ThompsonChief Operating Officer\, eureKARE \n\n\n\nVivian TsevelekiChief Operating Officer\, theraCell \n\n\n\nMore to be announced soon \n\n\n\nIntroduction \n\n\n\nIn April 2023\, the European Commission adopted a proposal for a new Directive and a new Regulation\, aimed at revising and replacing the existing General Pharmaceutical Legislation (GPL). The proposal focuses on modernising the pharmaceutical sector with a patient-centred approach\, while also fully supporting an innovative and competitive industry. \n\n\n\nThrough the proposal\, the EU aims to offer an attractive and innovation-friendly environment for research\, development\, and production of medicines in Europe. The EU plans to create this environment by promoting world-class innovation\, governed by stable and consistent rules that keep pace with innovation and which increase competitiveness while reducing red tape and costs. \n\n\n\nOne of the sectors impacted by the proposal is that of biotechnology\, which has been instrumental in the discovery and development of therapies\, diagnostics\, vaccines and\, most importantly\, advanced medicines. These ‘next generation medicines’ are delivered through a complex and interdependent biotechnology ecosystem\, where companies of all sizes contribute to establishing a pathway to patients. \n\n\n\nJoin this Euractiv Hybrid Conference to discuss Europe’s biotech innovation in light of the EU’s reform of the General Pharmaceutical Legislation.  \n\n\n\nQuestions to be discussed include: \n\n\n\n\nHow can Europe’s biotechnology industry maintain its competitiveness in the global medical market?\n\n\n\nHow can we establish a framework that fosters the growth of small biotech innovators?\n\n\n\nWhat are the reactions of investors to the challenges faced by small biotech companies\, and how do these reactions influence the trajectory of innovation in the biotech industry?\n\n\n\nWhat strategies can be employed to establish a successful innovation pathway for biotech companies\, while considering and aligning with the objectives of the reformed GPL?
URL:https://www.europabio.org/event/eu-pharmaceutical-legislation-europes-biotech-innovation-in-the-balance/
CATEGORIES:All,EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/EuropaBio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240110T080000
DTEND;TZID=Europe/Brussels:20240125T170000
DTSTAMP:20260729T061344
CREATED:20231213T130812Z
LAST-MODIFIED:20231213T131255Z
UID:7175-1704873600-1706202000@www.europabio.org
SUMMARY:IHI Call Days - Calls 6 & 7
DESCRIPTION:The IHI Call Days are your one-stop-shop to get detailed information on our calls for proposals and network with potential partners for your consortium. \n\n\n\nIHI call 7 (single-stage) – info sessions\n\n\n\n10-12 January 2024 \n\n\n\nCall 7\, topic 1: Improving clinical management of heart disease from early detection to treatmentWednesday 10 January | 10:30-11:30 \n\n\n\nCall 7\, topic 2: User-centric technologies and optimised hospital workflows for a sustainable healthcare workforceWednesday 10 January | 14:30-15:30 \n\n\n\nIHI rules and procedures for single-stage callsThursday 11 January | 10:30-11:30 \n\n\n\nCall 7\, topic 3: Clinical validation of biomarkers for diagnosis\, monitoring disease progression and treatment responseThursday 11 January | 14:30-15:30 \n\n\n\nManaging the financial aspects of proposals for single-stage callsFriday 12 January | 10:30-11:30 \n\n\n\nIHI call 6 (two-stage) – info sessions\n\n\n\n15-16 January 2024 \n\n\n\nIHI rules and procedures for two-stage callsMonday 15 January | 14:30-15:30 \n\n\n\nCall 6\, topic 2: Development of practical guidance and recommendations for using real world data/real world evidence in healthcare decision-makingTuesday 16 January | 10:30-11:30 \n\n\n\nCall 6\, topic 1: Support healthcare system resilience through a focus on persistency in the treatment of chronic diseasesTuesday 16 January | 14:30-15:30 \n\n\n\nIHI call 7 (single-stage) – pitching sessions\n\n\n\n23-25 January 2024 \n\n\n\nCall 7\, topic 1: Improving clinical management of heart disease from early detection to treatmentTuesday 23 January | 14:30-16:00 \n\n\n\nCall 7\, topic 2: User-centric technologies and optimised hospital workflows for a sustainable healthcare workforceWednesday 24 January | 14:30-16:00 \n\n\n\nCall 7\, topic 3: Clinical validation of biomarkers for diagnosis\, monitoring disease progression and treatment responseThursday 25 January | 14:30-16:00
URL:https://www.europabio.org/event/ihi-call-days-calls-6-7/
CATEGORIES:Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/news-cover.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231130T143000
DTEND;TZID=Europe/Brussels:20231130T160000
DTSTAMP:20260729T061344
CREATED:20231018T092656Z
LAST-MODIFIED:20231018T113625Z
UID:7003-1701354600-1701360000@www.europabio.org
SUMMARY:EuropaBio Patient BioForum 2023 Roundtable on Advancing Solutions for Unmet Medical Needs
DESCRIPTION:Hybrid Event | Invitation Only \n\n\n\n\n\nEuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. To address unmet medical needs (UMN)\, the Commission proposed as part of the revision of the EU General Pharmaceutical Legislation (GPL) to introduce a definition of UMN and a definition of high UMN. Under the Commission’s proposals\, all orphan products would qualify as addressing UMN but only a subset of products would meet the HUMN criteria. The Commission’s proposals on UMN and especially HUMN received mixed reactions from patient organisations and negative reactions from the industry. \n\n\n\nOn 1 December 2022\, EuropaBio organised a Patient BioForum which brought together industry and patient organisations to discuss the topic of UMN in view of reaching a common understanding on UMN. Those discussions revealed shared interests and concerns with the possible approach to UMN in the EU Pharmaceutical Legislation. The discussions were followed by a report which outlined recommendations to policymakers to enable Europe to address the challenge of UMN. \n\n\n\nWith the proposals now presented and being negotiated by the European Parliament and the Council\, the 2023 Patient BioForum is an opportunity to build on the 2022 Patient BioForum to foster exchanges between patient groups and industry on UMNs\, including expectations from the legislation and beyond. The 2023 Patient BioForum will also be an opportunity to issue multi-stakeholder recommendations to policymakers to ensure the GPL is fit for purpose to address patients need and support innovation.   \n\n\n\n \n\n\n\nProgramme \n\n\n\nThe 2023 Patient BioForum will be held in a roundtable format under Chatham House Rule. A wide range of stakeholders representing patients\, regulators\, policy-makers\, and industry will be invited to take part in the roundtable. All participants will be invited to take an active part in the discussion to bring their unique perspective. The roundtable will be followed by a report to summarise the discussions. \n\n\n\n1. Introductions \n\n\n\n2. Legislating Unmet Medical Needs: Perspectives from the European Commission and the European Parliament \n\n\n\n3. Roundtable topic 1:  How Can the EU Pharmaceutical Legislation Help Stimulate Patient-Centric Innovation? \n\n\n\n4. Roundtable topic 2: How can Europe Incentivise R&D for UMN and Underserved Areas? \n\n\n\n5. Conclusions \n\n\n\nIf you would like to attend\, please contact Adrian Lincoln\, a.lincoln@europabio.org
URL:https://www.europabio.org/event/europabio-patient-bioforum-2023-roundtable-on-advancing-solutions-for-unmet-medical-needs/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Event-Banners-Website-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231106T153000
DTEND;TZID=Europe/Brussels:20231106T163000
DTSTAMP:20260729T061344
CREATED:20231013T105949Z
LAST-MODIFIED:20231013T105951Z
UID:6985-1699284600-1699288200@www.europabio.org
SUMMARY:BIO Europe 2023
DESCRIPTION:The European Pharmaceutical Legislation – Will it keep the light on for biotech in Europe? \n\n\n\nJoin our Director General\, Dr. Claire Skentelbery on the 6th of November in Munich for her panel discussing what the legislation brings\, its potential impact on businesses and what needs to be done to change the legislation in its journey to a final version\, that it works for both\, the biotech ecosystem\, maintaining innovation pipelines\, and patients.
URL:https://www.europabio.org/event/bio-europe-2023/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-13-113155.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231101T080000
DTEND;TZID=Europe/Brussels:20231102T170000
DTSTAMP:20260729T061344
CREATED:20231013T082312Z
LAST-MODIFIED:20231013T082314Z
UID:6977-1698825600-1698944400@www.europabio.org
SUMMARY:World Orphan Drug Congress
DESCRIPTION:The World Orphan Drug Congress is the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. \n\n\n\nJoin our Director General\, Dr. Claire Skentelbery on the 1st of November for her Keynote Panel: How to navigate the new legislation to enable orphan drug developers to stay innovative and profitable in Europe. \n\n\n\nAs well as on the 2nd on November for her Panel: How to enable SME’s to obtain greater market access.
URL:https://www.europabio.org/event/world-orphan-drug-congress/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-13-101414.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231023T124000
DTEND;TZID=Europe/Brussels:20231023T141000
DTSTAMP:20260729T061344
CREATED:20231012T114428Z
LAST-MODIFIED:20231012T115640Z
UID:6973-1698064800-1698070200@www.europabio.org
SUMMARY:TOPRA Symposium 2023: advancing global healthcare together
DESCRIPTION:Session: Update on EU new regulatory legislation and a view from different angles \n\n\n\nJoin our very own Valentin Plouchard who will be speaking at the TOPRA Annual Symposium in Lisbon on the 23rd of October.
URL:https://www.europabio.org/event/topra-symposium-2023-advancing-global-healthcare-together/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-12-133359.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231011T133000
DTEND;TZID=Europe/Brussels:20231011T150000
DTSTAMP:20260729T061344
CREATED:20230920T110911Z
LAST-MODIFIED:20230920T110912Z
UID:6861-1697031000-1697036400@www.europabio.org
SUMMARY:SMEs in a Changing World: The Impact of the Revision of the Pharmaceutical Legislation on Europe’s innovative SMEs
DESCRIPTION:In April 2023\, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem. \n\n\n\nAs emerging and small companies have become innovation drivers\, responsible for over two-thirds of the R&D pipeline that will become the medicines of tomorrow\, changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, emerging and small companies looking to first enter the market but also on mid-size companies looking for growth opportunities in Europe. \n\n\n\nThis event will be an opportunity to highlight the role of small and mid-size companies in developing medicines for patients\, assess the foreseeable impacts of the revision on those companies\, and hear directly from them what they need from the revision to continue their journey in Europe.
URL:https://www.europabio.org/event/smes-in-a-changing-world-the-impact-of-the-revision-of-the-pharmaceutical-legislation-on-europes-innovative-smes/
CATEGORIES:EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/09/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230517T160000
DTEND;TZID=Europe/Brussels:20230517T163000
DTSTAMP:20260729T061344
CREATED:20230516T082719Z
LAST-MODIFIED:20230516T082807Z
UID:6226-1684339200-1684341000@www.europabio.org
SUMMARY:EU Healthcare and Pharmaceutical Policy in 2023: What You Need to Know
DESCRIPTION:From the ongoing revision of the EU pharmaceutical legislation package and addressing critical supply issues to the impact of the recent Medical Device Regulation transition period extension\, the challenges in EU healthcare and pharmaceutical policy are ever-evolving. Plus\, with the implementation of critical files\, such as the European Health Data Space (EHDS) and the Substances of Human Origin (SoHo) regulation\, it’s vital for organizations in this market to stay up-to-date with the latest policy and regulatory developments. \n\n\n\nTune in on May 17 at 4 pm CEST | 10 am EDT for a 30-minute recorded webinar that will delve into the latest updates in legislation and regulation that are shaping the future of healthcare\, pharmaceutical\, and medical device industries in Europe to help you navigate the next steps in this policy landscape. \n\n\n\nExperts will discuss: \n\n\n\n\nThe ongoing revision of EU pharmaceutical legislation\n\n\n\nTackling critical supply issues in pharmaceuticals and medical devices\n\n\n\nThe impact of the Medical Device Regulation transition period extension\n\n\n\nProposed and upcoming critical files you should be monitoring\n\n\n\nThe future of EU healthcare policy in 2023 and beyond\n\n\n\n\nFeatured speakers: \n\n\n\n\nAdrien Samson\, healthcare policy & public affairs senior manager\, EuropaBio\n\n\n\nJelle Verheij\, policy analyst – health and pharmaceuticals policy\, EU Issue Tracker\n\n\n\nModerator: Geraint Edwards\, managing director of FiscalNote Brussels\n\n\n\n\n\nMore Details
URL:https://www.europabio.org/event/eu-healthcare-and-pharmaceutical-policy-in-2023-what-you-need-to-know/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/General-Promo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230418T150000
DTEND;TZID=Europe/Brussels:20230418T160000
DTSTAMP:20260729T061344
CREATED:20230124T170639Z
LAST-MODIFIED:20230406T134218Z
UID:5708-1681830000-1681833600@www.europabio.org
SUMMARY:Development of Orphan Biologics: Challenges and Opportunities
DESCRIPTION:Webinar sponsored by Catalent \n\n\n\n\n\n\n\n\n\nThe development of therapies for rare diseases comes with distinct challenges\, including patient recruitment\, setting meaningful clinical endpoints\, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy. \n\n\n\nFor biologic products (growth factors\, monoclonal antibodies\, other complex proteins)\, development and production costs tend to be higher due to the complexity of the drug substance. To manage costs\, the clinical development and manufacturing and Chemistry\, Manufacturing and Controls (CMC) teams need to be aligned to ensure drug product is delivered on time to meet clinical trial needs. \n\n\n\nThese challenges sit within a wider regulatory and legislative framework for orphan medicinal products (OMPs) that defines whether companies can successfully develop a novel product to market and thus the decisions made for selecting therapeutics and target diseases early in development. \n\n\n\nDuring this webinar\, speakers cover aspects of clinical trial design for orphan biologics products\, key strategies for ensuring clinical trial supply throughout clinical development and the regulatory and legislative framework for delivery to patients.Key Learning Objectives \n\n\n\n\nConsiderations in identifying meaningful clinical endpoints for orphan diseases\n\n\n\nOrphan clinical trial design considerations and strategies to ensure sufficient patient recruitment\n\n\n\nManufacturing and clinical supply strategies to ensure supply of clinical trial materials while collecting data needed to support NDA submission\n\n\n\nRegulatory and legislative frameworks that guide decision making for innovation in rare diseases\n\n\n\n\nAgenda \n\n\n\n15:00: Welcome and introduction – Claire Skentelbery\, Director General EuropaBio \n\n\n\n15:05: Current Development of Orphan Drugs in Europe – Matthias Schoenermark\, Professor\, President and CEO\, SKC Beratungsgesellschaft mbH \n\n\n\nProf. Schönermark opens the session with an overview of the current status of orphan drug development in the EU. He discusses the main challenges for market entry of new orphan drugs into the EU market and highlights key recommendations to drug developers to address these challenges. \n\n\n\n15:20: Orphan Biologics and CGT Development – CMC and Clinical Trial Supply Considerations – Wai Lam Ling\, Ph.D.\, Vice President\, Science and Technology\,  Catalent \n\n\n\nDr. Ling discusses the difference in CMC challenges encountered during an orphan biologics vs CGT programme\, with a focus on product quality as the most significant hurdle to approval. She addresses manufacturing approaches to ensure regulatory compliance and factors behind a successful product\, particularly robust\, reproducible and cost-effective pathways. Finally\, supply chain liabilities are discussed\, with risks to production of biologics and their clinical supply. \n\n\n\n15:45: Successful Strategies and Business Model For Companies Bringing Their Orphan Drug To Market –Thomas Bols\, Head of Government Affairs and Patient Advocacy\, EMEA & APAC\, PTC Therapeutics \n\n\n\nThomas Bols addresses the spectrum of opportunities and barriers for innovation within orphan drug development\, particularly across different regulatory territories\, and the critical role of smaller companies in addressing unmet medical needs. He focuses on the legislative and regulatory pathways that exist in Europe for orphan drugs and the potential impact of the upcoming pharmaceutical and OMP legislation revisions for company innovation and patient benefits. \n\n\n\n16:00: Close \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/development-of-orphan-biologics-challenges-and-opportunities/
LOCATION:Catalent
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230228T110000
DTEND;TZID=Europe/Brussels:20230228T121500
DTSTAMP:20260729T061344
CREATED:20230117T135652Z
LAST-MODIFIED:20230118T100150Z
UID:5661-1677582000-1677586500@www.europabio.org
SUMMARY:SME BioForum: Rare diseases
DESCRIPTION:Rare Disease Day takes place on February 28th across the globe to raise awareness among policymakers and the public about rare diseases and their impact on patient’s lives and their families. \n\n\n\nBuilding on the latest SME BioForum on Advanced Therapy Medicinal Products (ATMPs)\, EuropaBio – the European Association for Bioindustries will mark this day by hosting an online\, invite-only SME BioForum solely dedicated to rare diseases. The event will take place from 11h00 to 12h15 CET. \n\n\n\nThe meeting is entirely SME driven. SME participants will connect with their peers\, share their experiences and discuss the current regulatory and incentives framework ahead of the revision of the pharmaceutical legislation and the legislation on orphan and pediatric medicines. \n\n\n\nIf you have any queries or want further details\, please get in touch with José Peres at j.peres@europabio.org. \n\n\n\n\nSME BioForum 2022 Report: Advanced Therapy Medicinal Products
URL:https://www.europabio.org/event/sme-bioforum-rare-diseases/
CATEGORIES:Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/SME-BioForum-Rare-Diseases_Event_Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221201T143000
DTEND;TZID=Europe/Brussels:20221201T160000
DTSTAMP:20260729T061344
CREATED:20221117T151753Z
LAST-MODIFIED:20221121T110237Z
UID:5532-1669905000-1669910400@www.europabio.org
SUMMARY:EuropaBio Patient BioForum 2022: Toward a Common Understanding of Unmet Medical Needs
DESCRIPTION:EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. Addressing unmet medical need was outline as a central to the 2020 Pharmaceutical Strategy for Europe. One perceived shortcoming of the current legislative frameworks is insufficient stimulated development in some areas of ‘unmet medical need’ (UMN) such as antimicrobial resistance or rare diseases. The upcoming revision of the EU pharmaceutical legislation and orphan and paediatric legislation will aim at addressing “unmet medical needs”. \n\n\n\nA major hurdle to overcome is reaching a common understanding of unmet medical needs as stakeholders have different understanding of the concept based on different perceptions and expectations. Unmet medical need is scientific concept which can be used to identify patient and societal health needs and stimulate research activities. As science progresses\, and with it the knowledge to address unmet medical needs\, these needs will evolve over time from improving mortality\, modifying disease progression\, improving quality of life\, burden of the disease\, and potentially curing. \n\n\n\nBringing together multiple stakeholder groups\, including patients and industry\, the 2022 Patient BioForum is an opportunity to listen to patients’ understandings and experiences with unmet medical needs and facilitate progress towards a common understanding on unmet medical needs. \n\n\n\n \n\n\n\nSpeakers \n\n\n\n\nJoelle Khraiche\, EuropaBio\, Patient BioForum co-chair\n\n\n\n\n\nAnca Toma\, EPF\, Patient BioForum co-chair\n\n\n\n\n\nTobias S. Hagedorn\, Secretary of European Society for Phenylketonuria (ESPKU) and Managing Director of DIG PKU Germany\n\n\n\n\n\nPedro Franco\, Director Europe for Global Regulatory & Scientific Policy at Merck and Chair of EuropaBio’s OMP WG\n\n\n\n\nModerator \n\n\n\n\nAdrien Samson\, Healthcare Biotechnology Manager\, EuropaBio\n\n\n\n\n\nInvitation Only Event
URL:https://www.europabio.org/event/europabio-patient-bioforum-2022-toward-a-common-understanding-of-unmet-medical-needseuropabio-patient-bioforum-2022/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Patient-BioForum-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220929T140000
DTEND;TZID=Europe/Brussels:20220929T150000
DTSTAMP:20260729T061344
CREATED:20220830T122553Z
LAST-MODIFIED:20220922T103100Z
UID:5064-1664460000-1664463600@www.europabio.org
SUMMARY:European Biotech Week 2022: At the cutting edge of biotechnology for cardiovascular diseases: A World Heart Day special edition webinar
DESCRIPTION:Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients\, both in terms of innovative treatments\, but also via use of innovative prevention\, screening\, and testing measures. \n\n\n\nDuring this webinar\, which marks World Heart Day\, speakers will discuss how biomarker testing for genetically inherited risk factors for cardiovascular diseases is opening up new frontiers in healthcare\, and saving lives across the world. \n\n\n\nFeaturing speakers from the patient community\, research and academia\, and industry\, the conversation will also address the need to translate guidelines into practice\, and will end with an interactive Q&A. \n\n\n\nSpeakers: \n\n\n\nMarius Geanta\, Trustee and the Chair of the Policy Advisory Committee\, FH EuropeLena Lymperopoulou\, Global Policy Head Therapeutic Area Cardiovascular\, NovartisFlorian Kronenberg\, Full Professor and Head of the Institute of Genetic Epidemiology\, Medical University of InnsbruckJamie Wilkinson\, Healthcare Biotechnology Director\, EuropaBio\n\n\n\n\nREGISTER NOW
URL:https://www.europabio.org/event/european-biotech-week-2022-hc/
CATEGORIES:Biotech Week,EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-HC.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220602T150000
DTEND;TZID=Europe/Brussels:20220602T161500
DTSTAMP:20260729T061344
CREATED:20220510T072627Z
LAST-MODIFIED:20220517T120255Z
UID:4513-1654182000-1654186500@www.europabio.org
SUMMARY:Rare Conversations 2022!
DESCRIPTION:Managing uncertainties in rare disease innovation\n\n\n\n\n\nJoins us for the new episode of Rare Conversations 2022! \n\n\n\nThe second episode of Rare Conversations 2022 will build on the previous Conversation about game-changing opportunities in rare disease R&D. In the first episode\, different experts convened on the existence of opportunities in rare diseases\, that still face obstacles that need to be addressed. This event is meant to discuss and propose solutions on: “Managing uncertainties in rare disease innovation”
URL:https://www.europabio.org/event/rare-conversations-2022-2/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220126T103000
DTEND;TZID=Europe/Brussels:20220126T130000
DTSTAMP:20260729T061344
CREATED:20211216T100649Z
LAST-MODIFIED:20220113T150518Z
UID:3584-1643193000-1643202000@www.europabio.org
SUMMARY:Introducing the Innovative Health Initiative: Europe’s new partnership for health
DESCRIPTION:The Innovative Health Initiative (IHI) aims to build on the successes of the Innovative Medicines Initiative (IMI) and will hold a launch event in a virtual setting on Wednesday\, January 26th\, from 10:30am to 1:00pm. \n\n\n\nThe event will be broken up into two sessions: \n\n\n\nIn the first session\, IHI Executive Director Dr Pierre Meulien will present IHI and explain why we are launching a new European partnership for health. He will also describe what’s new compared to the Innovative Medicines Initiative (IMI)\, and what will stay the same. IHI staff will then present opportunities for stakeholders to get involved in IHI\, for example by applying to become a member of the IHI Science and Innovation Panel (SIP)\, or by becoming an expert evaluator. They will also offer a preview of the draft topics under consideration for inclusion in the first IHI call for proposals. \n\n\n\nThe second session will feature a high-level discussion during which representatives of the IHI partners\, namely the European Commission\, COCIR\, EFPIA\, Vaccines Europe\, EuropaBio and MedTech Europe\, will present their vision for IHI. \n\n\n\nBoth sessions will include time for questions from participants. \n\n\n\n \n\n\n\n\nMore info here
URL:https://www.europabio.org/event/introducing-the-innovative-health-initiative-europes-new-partnership-for-health/
CATEGORIES:Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/12/Event-Banners.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211213T140000
DTEND;TZID=Europe/Brussels:20211213T150000
DTSTAMP:20260729T061344
CREATED:20211116T143909Z
LAST-MODIFIED:20211216T093602Z
UID:3429-1639404000-1639407600@www.europabio.org
SUMMARY:EuropaBio 25th Anniversary | mRNA: A voyage of discovery and celebration
DESCRIPTION:The existence of messenger(m) RNA was hypothesized early in the days of DNA breakthroughs in the 1960s\, and research from the 1990s started to reveal its potential as a therapeutic tool. \n\n\n\nmRNA became a household name in 2020 and 2021 as arguably the most important global breakthrough of recent years\, with its ability to create a specific proteins underpinning vaccine development in response to Covid-19.EuropaBio is delighted to host the final event of its 25th Anniversary programme with a focus on the story of mRNA. Its first steps into commercial development\, challenges to bring a vaccine to millions of people and life beyond Covid – the destination for mRNA in oncology and other significant health applications. \n\n\n\nWe bring together protagonists from across the spectrum\, including:• Ingmar Hoerr\, CureVac Founder and holder of the first patents associated with mRNA• Stephen Lockhart\, Head of EU/AP Vaccines Clinical R&D at Pfizer• Dhaval Patel\, Senior Manager\, Manufacturing & Technology\, Catalent Biologic
URL:https://www.europabio.org/event/europabio-25th-anniversary-mrna-a-voyage-of-discovery-and-celebration/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/11/Event-Banners-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211109T140000
DTEND;TZID=Europe/Brussels:20211109T180000
DTSTAMP:20260729T061344
CREATED:20211012T143142Z
LAST-MODIFIED:20211102T154338Z
UID:3283-1636466400-1636480800@www.europabio.org
SUMMARY:Rare Conversations Conference | European Rare Disease Ecosystem: A Collaborative Path Forward
DESCRIPTION:Join the inaugural Rare Conversations Conference aimed at facilitating essential discussion on the future of the rare disease and OMP ecosystem involving leading experts.The event will bring together thought leaders across regulators\, payers\, patient organizations\, research\, academia\, EU institutions\, industry and investors to develop inspiring ideas to advance the future of rare diseases. In four sessions\, speakers will cover the entire rare disease and orphan drug value chain from research through to access.Be part of this multifaceted and holistic approach to improving the rare disease ecosystem for the next decade and beyond in the EU through true multi-stakeholder exchange.The event is organized by Alexion in cooperation with the European rare disease patient organisation EURORDIS\, the European Joint Programme on Rare Diseases EJP RD\, the body for small to medium-sized innovative pharmaceutical\, biotechnology and medical technology companies EUCOPE\, and the association of the biotech industry EuropaBio.Block your calendar for 9th November from 14.00 – 18.00 CET. More information and the registration link will be shared with you shortly. \n\n\n\n\n\n\n\nAbout “Rare Conversations”Rare Conversations is an event series organized by Alexion to educate on rare diseases and facilitate multi-stakeholder exchange\, tackling timely topics of interest such as the revision of the OMP Regulation. Rare Conversations aims to unite and engage the rare disease community\, including key stakeholders in Brussels and EU Member States. Since its inception in December 2020\, four Rare Conversations have taken place\, each in cooperation with a different partner and focused on specific topics\, such as COVID and rare diseases\, the specificities of research in rare disease\, and EU and national value assessment for orphan drugs. People with rare diseases always stay at the centre of our activities and are part of every event.
URL:https://www.europabio.org/event/rare-conversations-conference-european-rare-disease-ecosystem-a-collaborative-path-forward/
CATEGORIES:Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/10/Rare-Conversations.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211014T100000
DTEND;TZID=Europe/Brussels:20211014T120000
DTSTAMP:20260729T061344
CREATED:20211012T142747Z
LAST-MODIFIED:20211012T142747Z
UID:3280-1634205600-1634212800@www.europabio.org
SUMMARY:EU4Health 2021 Work Programme | Info Session on HERA Procurement Calls
DESCRIPTION:The European Health and Digital Executive Agency (HaDEA) with the support of the European Commission organizes an info session to present three HERA’s public procurement calls launched under the EU4Health work programme 2021 (C(2021)4793 final):–  HADEA/2021/OP/0005 – A Study on Bringing AMR Medical Countermeasures to the Market– HADEA/2021/OP/0006 – Feasibility Study on Stockpiling of Medical Countermeasures in the Area of AMR– HADEA/2021/OP/0009 – Feasibility Study\, Design and Prototype Development for a Mapping Platform on COVID-19 Therapeutics in the EU
URL:https://www.europabio.org/event/eu4health-2021-work-programme-info-session-on-hera-procurement-calls/
CATEGORIES:Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/10/Eu4Health.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210927T080000
DTEND;TZID=Europe/Brussels:20211003T080000
DTSTAMP:20260729T061344
CREATED:20210128T134240Z
LAST-MODIFIED:20210610T122254Z
UID:948-1632729600-1633248000@www.europabio.org
SUMMARY:European Biotech Week 2021
DESCRIPTION:The European Biotech Week celebrates biotechnology\, an innovative and vibrant sector launched by the discovery of the DNA molecule back in 1953. The first European Biotech Week that took place in 2013 marked the 60th anniversary of this pivotal moment in history. \n \n 
URL:https://www.europabio.org/event/european-biotech-week-2021/
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/European-Biotech-Week-Event-Banner-.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210920T090000
DTEND;TZID=Europe/Brussels:20210921T170000
DTSTAMP:20260729T061344
CREATED:20210210T200303Z
LAST-MODIFIED:20210628T201352Z
UID:1320-1632128400-1632243600@www.europabio.org
SUMMARY:German Biotechnology Days
DESCRIPTION:Germany’s largest biotech event\, the German Biotechnology Days 2021 (Deutsche Biotechnologietage\, DBT)\, will take place on 20th and 21st September in Stuttgart. With over 800 participants\, the event is regarded as the German class reunion for biotechnology. The DBT brings together entrepreneurs with scientists and partners from politics\, funding institutions and administration. \n\n\n\nIn plenary sessions and numerous symposia\, top-class speakers present and discuss the diverse fields of application and the potential of biotechnology\, from health research to bioeconomy\, from medicine to industrial production and plant breeding. Exchange and networking traditionally play a major role at the DBT. The big evening event on the first day of the conference is therefore a further highlight. In addition to the conference programme\, there will also be a large exhibition. \n\n\n\nThe German Biotechnology Days are jointly organised by BIO Deutschland and the Council of German BioRegions. The host region for 2021 is STERN BioRegion from Stuttgart. As a partner region\, we are looking forward to BioLAGO\, the network for the health industry in the Lake Constance region. \n\n\n\nAbout the organizersBIO Deutschland e. V.\, the industry association of the German biotechnology industry\, and the Council of German BioRegions have been jointly organising the German Biotechnology Days since 2010. The forum for the German biotechnology scene takes place annually at different locations. The regional host of the event is always a bioregion from the Council of German BioRegions\, often accompanied by a partner region. \n\n\n\n\nVIRTUAL EVENT \n \n\n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/german-biotechnology-days/
LOCATION:BIO Deutschland\, Schützenstraße 6a\, Berlin\, D-10117\, Germany
CATEGORIES:External,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-DBT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210907T160000
DTEND;TZID=Europe/Brussels:20210907T170000
DTSTAMP:20260729T061344
CREATED:20210715T095059Z
LAST-MODIFIED:20210903T072658Z
UID:2936-1631030400-1631034000@www.europabio.org
SUMMARY:Treatment without borders: the EU case for equitable patient access to advanced therapies
DESCRIPTION:The EU Pharmaceutical Strategy is looking to improve patients’ access to therapies for challenging and rare conditions. The EU legislation on cross-border healthcare is an important instrument to ensure patient access to the best available care. There is an urgent need to revise this legislation to enable EU patients to access novel advanced therapies and medicines for rare diseases when these are not available in their home country. \n\n\n\nEuropaBio’s Advanced Therapies Series continues with a virtual discussion on avenues for enhancing the access of EU patients to novel biotechnology-derived treatments on September 7\, 2021\, from 16h00 to 17h00 CET. \n\n\n\nA patient who is also actively engaged in patient advocacy will explain the value of advanced therapies for rare disease patients and the key challenges they encounter when accessing treatments outside their home countries. \n\n\n\nA panel of EU\, national\, and industry representatives will attempt to put forward solutions for securing equitable access to both specialised centres and to treatment for all EU patients in need. Among others\, they will seek to advise on how to tackle the following challenges: some treatment centres being less interested to treat cross-border patients\, the need for experience and expertise in rare diseases\, approval process and time for cross-border treatment\, lack of knowledge or experience of healthcare providers in requesting reimbursement for cross-border treatments\, difficulties in approving advanced therapy applications if not reimbursed in the home country\, etc. \n\n\n\nModerator \n\n\n\nBernard Grimm\, Healthcare Biotech Director\, EuropaBio \n\n\n\nSpeakers  \n\n\n\nJana Popova\, Executive Committee Member of the European Alliance of Neuromuscular Disorders Associations & EUPATI Patient Engagement Training Coordinator \n\n\n\nBrieuc Van Damme\, Director-General Healthcare\, RIZIV-INAMI \n\n\n\nMartin Dorazil\, Deputy Head of Unit\, DG Health\, European Commission \n\n\n\nDirk Vander Mijnsbrugge\, Vice President Medical Affairs Lead Rare Diseases International Developed Markets\, Pfizer \n\n\n\nIrina Grossenbacher\, Region Europe Patient Access Director\, Novartis Rare Diseases \n\n\n\nTomislav Sokol\, Member of the European Parliament\, EPP\, Croatia
URL:https://www.europabio.org/event/treatment-without-borders-the-eu-case-for-equitable-patient-access-to-advanced-therapies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/07/NL-Size-28.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210712T090000
DTEND;TZID=Europe/Brussels:20210713T170000
DTSTAMP:20260729T061344
CREATED:20210623T145655Z
LAST-MODIFIED:20210623T150119Z
UID:2771-1626080400-1626195600@www.europabio.org
SUMMARY:EU Matchmaking Event on COVID-19 Therapeutics
DESCRIPTION:Building on the experience of the EU Task Force for Industrial Scale-up of COVID-19 vaccines\, the European Commission will facilitate cooperation between actors in the supply chain to ensure that available therapeutics are produced in sufficient quantity as soon as possible. In the context of a surge in demand\, it remains crucial to ensure the speedy production of current and new therapeutics against COVID-19. To support the industry\, the Commission organises the pan-EU matchmaking events for all supply chain actors\, so that they find solutions for the bottlenecks encountered. \n\n\n\nMedicines for COVID-19 are still in the development phase. Therefore\, the objective of the event is to help accelerate the development of new and repurposed medicines for COVID-19 therapeutics\, i.e. medicines specifically developed for an indication in treatment of COVID-19\, at all stages of COVID-19 disease and mobilise the EU pharma manufacturing capacity for their potential production. \n\n\n\nThe target group is the entire EU COVID-19 therapeutics value chain starting with researchers and developers\, through manufacturing companies and representatives of the hospitals\, who apply such therapeutics to their patients. The providers of ancillary functions such as clinical trials services\, accessories suppliers (e.g. vials\, syringes\, tubes etc.)\, funding providers and public procurers will also be targeted to take part in the event. \n\n\n\nThe event will take place virtually on 12th and 13th July 2021. 12th July will start with a half-day seminar setting the scene with a welcome by Commissioner Breton and Commissioner Kyriakides. \n\n\n\n\n\n\n\nHow to apply? \n\n\n\nIn order to apply to the event\, European companies must comply with the requirements stated in the event’s Call for Expression of Interest. Register until June 25.
URL:https://www.europabio.org/event/eu-matchmaking-event-on-covid-19-therapeutics/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/06/European-Matchmaking-event-e1624460170563.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210603T140000
DTEND;TZID=Europe/Brussels:20210603T150000
DTSTAMP:20260729T061344
CREATED:20210315T132511Z
LAST-MODIFIED:20210602T083815Z
UID:1616-1622728800-1622732400@www.europabio.org
SUMMARY:EU Healthcare Biotech Policy Priorities for SMEs
DESCRIPTION:Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the ongoing revision of the basic pharmaceutical legislation and of regulations for medicines for rare and paediatric diseases\, SMEs should be planning how they build and grow their businesses\, whether within the EU or outside. \n\n\n\nAbout the EuropaBio SME Platform \n\n\n\nThe SME platform is a community of SMEs across all sectors in Europe\, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders. \n\n\n\n  \n\n\n\n\nREGISTER HERE\n\n\n\n\n\n\n\n\n 
URL:https://www.europabio.org/event/eu-healthcare-biotech-policy-priorities-for-smes/
CATEGORIES:EuropaBio,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-9-1.png
END:VEVENT
END:VCALENDAR